IL-6 and ASCVD more links....Direct Interleukin-6 Inhibition Blunts Arterial Thrombosis by Reducing Collagen-Mediated Platelet Activation | Arteriosclerosis, Thrombosis, and Vascular Biology ahajournals.org/doi/10.1161/AT…

🚨 Help us choose the host city for the 1st International #ICE_T Conference in 2027! 🌍 🏙️ Top 3 cities announced—your vote decides the winner! 1) Dubai 🇦🇪 2) Barcelona 🇪🇸 3) Istanbul 🇹🇷 🎟️ Vote now for a chance to WIN a trip to the event! Will announce the winning cities

Benchmarking of bioinformatics tools for the hybrid de novo assembly of human and non-human whole-genome sequencing data pubmed.ncbi.nlm.nih.gov/40703096/ 🧬🖥️🧪 github.com/genomicsITER/h…

Our upcoming #DevPres webinar focusses on stem cells and organoids, with talks from Toshi Yamada (UCSF), Chrysanthi-Maria (Anthie) Moysidou (Max Delbrück Center) & Daniel Medina-Cano Daniel Medina Cano (Memorial Sloan Kettering Cancer Center). 13 August 16:00 BST Register here: us02web.zoom.us/webinar/regist…

A new drug that blocks fat metabolism in the liver enables B cells to target and destroy #LiverCancer tumors, offering a potential advance for patients with #FattyLiverDisease–related #Cancer. @mcmastereng @nature doi.org/g9vttp medicalxpress.com/news/2025-07-d…

Where are we on microbiome research transition from bench to bedside? Jack A Gilbert (he/him/his) & Katrine Whiteson share how their envision the field in the near future: loom.ly/O7k9Omg

It was an amazing meeting, great people, great talks, great ideas and a lot of fun!

The 1-year results of the TriCLASP study support the safety and effectiveness of transcatheter edge-to-edge repair with the PASCAL system in patients with ≥severe tricuspid regurgitation, demonstrating meaningful clinical, functional, and quality-of-life improvements.

What is it like to be an Arabic woman building a career in thoracic oncology? On this episode of #LungCancerConsidered in Arabic, Dr. Nagla Abdel Karim, @asrar_alahmadi & Maya K. Khalil, MD discuss their professional journeys & the impact of representation in the field. 🎧

Preclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer dlvr.it/TMPZqn #genetherapy #celltherapy

A wonderful resource for scientists & trainees from my MD Anderson Cancer Center colleague Richard Behringer. A set of 12 “talking points” on how key discoveries in developmental biology have had major impact on biomedical research. Available from Society for Developmental Biology website: sdbonline.org/devbio_talking…

We’ve raised $30M to build the foundational dataset for Virtual Cell Models: 1Bn single-cell datapoints, mapping 1M drug-patient interactions, to be shared with one partner. Our goal: Move the frontier - From models to precision medicines that help patients. Tahoe Therapeutics 🧵

Without post hoc analyses and academic research, the extensive biological differences between sexes would remain overlooked. Evidence from neurology, cardiology, immunology, oncology, and endocrinology shows that assuming men and women respond identically to diagnoses, disease

Routine use of AI reduced health professionals’ abilities to detect precancerous growths without the technology, according to researchers. eu1.hubs.ly/H0mmFYH0

AI use is common among health systems. Fleshed-out governance is not, new survey finds bit.ly/46ShVBS

🌹Meet #ROSIE, our new AI that predicts spatial multi-protein expression straight from routine H&E images. Built on a large co‑staining dataset (>1k samples, 16M+ cells). It enables cell phenotyping & tissue structure insights w/o extra assays.

Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases dlvr.it/TMYps4 #MTMCD

Incorporating large language models (#LLM) as #clinical decision support in #oncology: the Woollie model | npj Digital Medicine nature.com/articles/s4174… #MedTwitter #AImedicine #AI #HealthAI #AIinHealthcare #MedTech

Opinion 🗣️ Current safety standards can’t keep up with AI, writes Yvette Khozam, electronic prescribing and medicines administration (ePMA) lead pharmacist at West London NHS Trust. eu1.hubs.ly/H0msxKm0

🌟🚀 Novel trial designs in the era of molecular oncology🌟 By Razelle Kurzrock, MD, UCSD Hematology/Oncology Fellowship, Lực Morris, Memorial Sloan Kettering Cancer Center The Tisch Cancer Institute, AACR President Lillian L. Siu AMERICAN CA: A Cancer Journal for Clinicians American Cancer Society 🔑 Key insights: ✅ Molecular reclassification is reshaping cancer trial paradigms ✅ Basket